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Summary
Background Chewing tobacco and other types of smokeless tobacco use have had less attention from the global health 
community than smoked tobacco use. However, the practice is popular in many parts of the world and has been 
linked to several adverse health outcomes. Understanding trends in prevalence with age, over time, and by location 
and sex is important for policy setting and in relation to monitoring and assessing commitment to the WHO 
Framework Convention on Tobacco Control.
Methods We estimated prevalence of chewing tobacco use as part of the Global Burden of Diseases, Injuries, and Risk 
Factors Study 2019 using a modelling strategy that used information on multiple types of smokeless tobacco products. 
We generated a time series of prevalence of chewing tobacco use among individuals aged 15 years and older from 
1990 to 2019 in 204 countries and territories, including age-sex specific estimates. We also compared these trends to 
those of smoked tobacco over the same time period.
Findings In 2019, 273·9 million (95% uncertainty interval 258·5 to 290·9) people aged 15 years and older used 
chewing tobacco, and the global age-standardised prevalence of chewing tobacco use was 4·72% (4·46 to 5·01). 
228·2  million (213·6 to 244·7; 83·29% [82·15 to 84·42]) chewing tobacco users lived in the south Asia region. 
Prevalence among young people aged 15–19 years was over 10% in seven locations in 2019. Although global age-
standardised prevalence of smoking tobacco use decreased significantly between 1990 and 2019 (annualised rate of 
change: –1·21% [–1·26 to –1·16]), similar progress was not observed for chewing tobacco (0·46% [0·13 to 0·79]). 
Among the 12 highest prevalence countries (Bangladesh, Bhutan, Cambodia, India, Madagascar, Marshall Islands, 
Myanmar, Nepal, Pakistan, Palau, Sri Lanka, and Yemen), only Yemen had a significant decrease in the prevalence of 
chewing tobacco use, which was among males between 1990 and 2019 (–0·94% [–1·72 to –0·14]), compared with nine 
of 12 countries that had significant decreases in the prevalence of smoking tobacco. Among females, none of these 
12 countries had significant decreases in prevalence of chewing tobacco use, whereas seven of 12 countries had a 
significant decrease in the prevalence of tobacco smoking use for the period.
Interpretation Chewing tobacco remains a substantial public health problem in several regions of the world, and 
predominantly in south Asia. We found little change in the prevalence of chewing tobacco use between 1990 and 2019, 
and that control efforts have had much larger effects on the prevalence of smoking tobacco use than on chewing 
tobacco use in some countries. Mitigating the health effects of chewing tobacco requires stronger regulations and 
policies that specifically target use of chewing tobacco, especially in countries with high prevalence.
Funding Bloomberg Philanthropies and the Bill & Melinda Gates Foundation.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Effective design of tobacco-control policies and appro-
priate allocation of resources requires understanding 
patterns and trends in all types of tobacco use.1 Although 
138 (77%) of the 180 countries committed to the aims of 
the WHO Framework Convention on Tobacco Control 
(FCTC) include smokeless tobacco in their statutes,2 
smokeless tobacco use has been monitored in far fewer 
countries than has smoking tobacco use, even in places 
with high prevalences of smokeless tobacco use.2 Only 
55 (31%) FCTC countries have data on adult smokeless 
tobacco use from the past 10 years, and only 70 (39%) have 
data on smokeless tobacco use among young people.2 
Additionally, smoked and smoke less tobacco use patterns 
differ by demographic, socio eco nomic, and cultural 
characteristics,3–6 so detailed informa tion on smokeless 
tobacco use patterns and trends are needed to tailor 
interventions that best meet the needs of these different 
subgroups.
Monitoring of smokeless tobacco use alongside smoked 
tobacco use should be done for a variety of reasons, 
including beliefs that it is a safe alternative to smoking, 
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beliefs about a variety of benefits (eg, for morning sick-
ness), and local distribution and production.6–8 Moreover, 
smokeless tobacco is less regulated than smoked tobacco. 
Tobacco manufacturers can sell smokeless tobacco pro-
ducts that are sweeter or flavoured and aimed at new 
users,9 and these products are usually cheaper than 
cigarettes.10 A wide array of products is available in the 
market, but data on smokeless tobacco use are often 
not collected by specific products or subtypes, further 
complicating monitoring and regulation. Although all 
smokeless tobacco products are consumed through the 
mouth or nose without burning, the wide variety of 
products are used in different ways11 and are associated 
with varying degrees and types of harm.12–14 This study 
focuses on chewing tobacco use, because the associated 
health risks are well documented.12,15,16 Many studies have 
found strong evidence for the increased risk of oral cancer 
due to chewing tobacco.11,14,17
In this context, we aimed to provide an improved 
understanding of chewing tobacco use, which is essential 
for targeted policy, assessment of the effectiveness of 
these policies, and, ultimately, mitigation of the associated 
harms.1 Studies have been done previously that estimated 
prev a lence for a particular country,18–20 region,3,4,21 or 
source,3,18–21 or a restricted time period11,20,21 or age group,5,22 
but to our knowledge no attempt has been made to synth-
esise multiple data sources to understand these trends 
globally over time and across age groups. For the first 
time, as part of the Global Burden of Diseases, Injuries, 
and Risk Factors Study (GBD) 2019, we compre hensively 
estimated the prevalence of chewing tobacco use using 
all available data sources to estimate age-sex-specific 
prevalence of chewing tobacco use from 1990 to 2019 
in 204 countries and territories. We also compared these 
trends with those of smoked tobacco over the same time 
period.23 This manuscript was produced as part of the 




We modelled prevalence of current chewing tobacco 
use by using data on multiple types of smokeless tobacco 
use. We defined current chewing tobacco use as use of 
chewing tobacco products within the past 30 days on either 
a daily or occasional basis, or current use as defined by the 
survey. We produced estimates for males and females 
separately, and for each 5-year age group between the ages 
of 15 and 94 years with a terminal age group of individuals 
aged 95 years and older. We produced estimates for 
every year between 1990 and 2019 and for 204 countries 
and territories included in GBD 2019. This study adheres 
to the Guidelines for Accurate and Transparent Health 
Estimates Reporting.24
Research in context
Evidence before this study
Previous studies of smokeless tobacco use have found that both 
prevalence and the type of product used vary widely across 
countries. Studies on the health effects of smokeless tobacco 
products have found differences in toxicity by type of product, 
with chewing tobacco products being the most harmful. 
Limitations of available survey data have posed a challenge to 
estimating internally consistent and comparable estimates of 
product-specific prevalence, disaggregated by location, age, 
sex, and time period. These limitations have made it difficult to 
form a comprehensive, global picture of where chewing 
tobacco is used most, among which age groups and sexes, 
and how this has changed over time.
Added value of this study
This study, based on results from the Global Burden of 
Diseases, Injuries, and Risk Factors Study 2019, is the first 
global analysis of prevalence of chewing tobacco use by age, 
sex, and time period that incorporates information from 
available nationally representative surveys with questions 
about smokeless tobacco use. To address the challenge of 
heterogeneous survey data, of which little were available, we 
developed and implemented a new approach to combining 
different definitions and sources of smokeless tobacco 
prevalence data across locations to mitigate the effects of 
compositional bias in the available data. These methods 
improved estimates, particularly in locations that have less 
chewing tobacco-specific data but do have data on other 
smokeless tobacco products. This modelling approach allowed 
for the use 752 data sources, integral to producing improved 
estimates by age, sex, and location, across which prevalence of 
chewing tobacco use varies widely. Finally, we compared trends 
in chewing tobacco with trends in smoking prevalence. 
The difference in trends over time between prevalences of 
chewing and smoking tobacco indicates that tobacco control 
efforts and policies have had a much larger effect on the 
prevalence of smoking tobacco use than on the prevalence of 
chewing tobacco use.
Implications of all the available evidence
Monitoring of prevalence of chewing tobacco use would benefit 
greatly from concerted efforts to add questions about its use in 
surveys that clearly distinguish the types of products, in a 
similar way to what is done for smoking tobacco. We found that 
the prevalence of chewing tobacco use has remained fairly 
stable over time and is high in many regions and demographic 
groups, including those with historically lower prevalence of 
smoking tobacco. Increased commitment to control of 
smokeless tobacco through both local interventions and 
expansion of the policies outlined in the WHO Framework 
Convention on Tobacco Control articles to smokeless tobacco 
products is urgently needed.
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See Online for appendix 
For the GBD 2019 Data Input 
Sources Tool see http://ghdx.
healthdata.org/gbd-2019/
data-input-sources
Because data on chewing tobacco alone are sparse, 
we systematically reviewed, extracted, and included in 
our estimations data on all types of smokeless tobacco. 
We classified data into three categories: chewing tobacco 
products only, non-chewing tobacco products only, and 
general smokeless tobacco with products not specified; 
we refer to this third category as unspecified smokeless 
tobacco. The first and second categories are distinct and 
do not overlap. Available data in these two categories 
were used to adjust data reported as general smokeless 
tobacco, which comprises the majority of data sources. 
As a result, in our modelling process we used information 
from all three categories to produce our final estimates of 
prevalence of chewing tobacco use for all countries.
Data sources
We searched the Global Health Data Exchange for 
representative surveys with data on use of any smokeless 
tobacco product among individuals aged 10 years and 
older collected between 1980 and 2019. Although we 
report data for individuals aged 15 years and older and 
from 1990 onwards, we included this additional age group 
and decade to inform time trends and age patterns of 
the model. We included individual-level survey data, tabu-
lated survey report data, and data from scientific litera ture. 
We identified and extracted data from 752 surveys that 
were location and year specific that met our inclusion 
criteria. Of 204 countries and territories, 185 (91%) had at 
least one data source and 58 (28%) had at least five data 
sources. 57 countries (28%) had their most recent data 
source from either 2017 or 2018. Full details on inclusion 
criteria, search strings, and extraction methods are 
included in the appendix (pp 12–15). A list of all included 
surveys can be accessed through the GBD 2019 Data Input 
Sources Tool.
Modelling strategy and overview of spatiotemporal 
Gaussian process regression
A key challenge in modelling the prevalence of chewing 
tobacco use is that 562 (75%) of 752 sources with 
information on smokeless tobacco did not distinguish 
between specific smokeless tobacco products. Because 
this large proportion of sources reported on unspecified 
smokeless tobacco use, we used a modelling strategy that 
maximised the use of available information, rather than 
constraining our analysis to only focus on sources 
reporting the prevalence of chewing tobacco use alone. 
An overview of the modelling strategy, from data pro-
cessing to final prevalence estimates, is shown in the 
appendix (p 23).
In three different parts of the estimation process, 
we used spatiotemporal Gaussian process regression 
(ST-GPR) to model location-age-sex-specific trends over 
time. Details on ST-GPR are described in full elsewhere.25 
Briefly, the model is implemented in three steps: first, 
linear regression; second, spatiotemporal smoothing, 
which adjusts the linear regression estimate on the basis 
of residuals weighted by distance in time, age, and 
location; and finally, Gaussian process regression, which 
incorporates uncertainty in the data and quantifies the 
uncertainty of the estimates. For all ST-GPR models, we 
used an agnostic first-stage linear model that only includes 
a global intercept and age fixed effects. As a result, 
variations in final estimates by time, location, and age 
were entirely data driven and were incorporated in the 
second and third stages of the model. The information 
sharing across similar locations in ST-GPR is particularly 
useful in this context because the proportion of chewing 
tobacco use versus non-chewing tobacco use appears to be 
very similar within geographical regions.11 Additionally, 
we do not believe that these trends over age and time 
are substantially affected by different survey methods 
(appendix p 20). The end result of ST-GPR is 1000 draws 
from the posterior distribution of the Gaussian pro-
cess, from which we calculated the mean and 2·5th 
and 97·5th percentiles to characterise the 95% uncertainty 
interval (UI).
Smokeless tobacco product mapping and generation of 
the prevalence model
Case definitions varied substantially across data sources. 
Surveys reported on 262 unique combinations of smoke-
less tobacco products, which we mapped to one of two 
mutually exclusive and collectively exhaustive categories: 
either chewing tobacco products or non-chewing tobacco 
products. Non-chewing tobacco products refers to smoke-
less tobacco products that are not chewing tobacco. In 
some cases, surveys did not specify a product, or specified 
a wide array of products that spanned both categories. 
We mapped these sources to a third category of unspeci-
fied smokeless tobacco. The product map is in the 
appendix (p 15). After product mapping, 170 sources 
reported on the prevalence of chewing tobacco use, 
137 reported on the prevalence of non-chewing tobacco 
use, and 690 reported on the prevalence of unspecified 
smokeless tobacco use.
After product mapping, 141 (19%) of 752 sources reported 
data only in aggregated age groups or as both sexes 
combined. We split these data into our standard 5-year age 
groups by sex. To do so, we ran separate ST-GPR models 
for each of the product categories (chewing tobacco, non-
chewing tobacco, and unspecified smokeless tobacco), 
using only data originally available in our standard 5-year 
age groups and separately by sex. In these models, we 
purposefully tuned the parameter con trolling the decay 
function for age weights in the spatio temporal smoothing 
step to ensure that age patterns were data driven rather 
than model driven. We then used the modelled estimates 
to generate age and sex ratios that included uncertainty 
and varied by location and year. We applied these ratios to 
the data originally reported in aggregated age groups or as 
both sexes combined to split the aggregated data into our 
target demographic groups. Additional details on these 
methods are in the appendix (pp 16–17).
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The proportion of unspecified smokeless tobacco that 
is chewing tobacco varies widely across countries. For 
example, in Sweden, snus (pulverised tobacco for sub-
labial administration, which we classify as non-chewing 
tobacco)26 is the predominant product used, while in India, 
most users of smokeless tobacco use chewing tobacco.6 
To include data sources that report the prevalence of 
unspecified smokeless tobacco use, we needed an estimate 
of the proportion of unspecified smokeless tobacco that is 
chewing tobacco in each country.
To arrive at that proportion, first we ran separate models 
for chewing tobacco and non-chewing tobacco, using all 
available data for each indicator. Then, based on the 
results of these models, we estimated an age-sex-location-
year-specific ratio of chewing tobacco as a proportion of 
chewing and non-chewing tobacco. Finally, we used this 
estimated ratio to adjust data reported as prevalence of 
unspecified smokeless tobacco use. We added the variance 
of the estimated ratio to the original variance of the data to 
reflect the uncertainty in this adjustment.
The final step in our modelling process was a ST-GPR 
model that included all data reported as prevalence of 
chewing tobacco use, and data reported as unspecified 
smokeless tobacco that have been adjusted on the basis of 
the estimated product type ratio. Because data variance is 
an input to ST-GPR, datapoints with higher variance had a 
lower influence on final estimates than did data points with 
a lower variance. As a result, the adjusted datapoints added 
information to the final model, but were weighted less in 
the final estimation than datapoints that were reported 
directly as prevalence of chewing tobacco use. Additional 
details of these methods are in the appendix (pp 18–20).
Statistical analysis
We report the prevalence of chewing tobacco use and the 
number of people that currently use chewing tobacco, by 
location, year, age, and sex, as well as age-standardised 
estimates for individuals aged 15 years and older, all with 
their respective 95% UIs. Similarly we report prevalences 
by sex among individuals aged 15–19 years. We calculated 
annualised rates of change to assess time trends and 
compare changes across time with those observed for the 
prevalence of smoking tobacco use. We calculated all 
results (including annualised rates of change) that are 
reported as geographical aggregations using population-
weighted aggregation. We determined annualised rates 
of change to be significant if the 95% UI did not include 
zero. We considered prevalence results to be significantly 
different if their 95% UIs did not intersect.
Details on modelling the prevalence of smoking tobacco 
use have been published separately.23 Additionally, we did a 
sensitivity analysis comparing the results of this main 
method (using both chewing tobacco and adjusted 
unspeci fied smokeless tobacco data) versus the results of 
using only the data on chewing tobacco (appendix 
pp 28–29).
We did all analyses using R (version 3.6.3).
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report.
Results
Globally, 273·9 million (95% UI 258·5–290·9) people used 
chewing tobacco in 2019 (appendix pp 62–69). The global 
age-standardised prevalence of chewing tobacco use 
in 2019 among people aged 15 years and older was 
4·72% (4·46–5·01) and was 6·55% (6·10–7·03) among 
males and 2·87% (2·60–3·14) among females (table). 
Most people (228·2 million [213·6–244·7]; 83·29% 
[82·15–84·42]) who used chewing tobacco in 2019 resided 
in the south Asia region. The largest populations of people 
who use chewing tobacco are in India (185·8 million 
[171·3–202·5] users; 67·83% [65·77–69·75] of global users) 
and Bangladesh (25·7 million [23·7–27·6]; 9·37% 
[8·59–10·25] of global users. Nepal, Bhutan, and Palau also 
had very high prevalences of chewing tobacco use in 
2019, with 4·4 million (4·1–4·8) users in Nepal, 113 040 
(102 587–123 860) in Bhutan, and 3440 (3090–3819) in 
Palau. Among males aged 15 years and older in 2019, the 
age-standardised prevalence in south Asia was 24·65% 
(22·81–26·69), while the lowest prevalence globally was 
0·17% (0·15–0·20) in southern Latin America (figure 1; 
appendix p 70). Similarly, the age-standardised prevalence 
for females in south Asia was 12·13% (10·91–13·45) 
in 2019, much greater than the lowest age-standardised 
prevalence globally, which was in western Europe (0·15% 
[0·14–0·17]; figure 1; appendix p 69). Outside of the south 
Asia region, the countries with the highest prevalence of 
chewing tobacco use in 2019 were, for males, Palau (25·76% 
[22·37–29·75]), Madagascar (16·98% [14·66–19·30]), 
Myanmar (14·18% [11·94–16·53]), and Sri Lanka (13·57% 
[11·39–15·77]; figure 1; appendix pp 30–37). For females, 
the highest prevalence of use was observed in Palau 
(24·42% [20·04–29·17]), Cambodia (12·84% [11·05–14·70]), 
Laos (6·73% [5·31–8·24]), and Botswana (6·54% 
[5·32–7·92]; figure 1; appendix pp 30–37).
Globally, prevalence of chewing tobacco use has 
increased slightly over time. The annualised rate of 
change between 1990 and 2019 for both sexes combined 
was 0·46% (95% UI 0·13 to 0·79), and was 0·39% 
(–0·01 to 0·83) for males and 0·60% (0·04 to 1·11) for 
females (appendix p 23). We identified high-prevalence 
locations by ranking the age-standardised prevalence of 
both sexes in 1990 and 2019. Here we concentrate on 
the 12 countries with the highest prevalence in either 
1990 or 2019, or both. Within these countries, males in 
Yemen and females in Palau were the only demographic 
groups that had significant changes in prevalence 
between 1990 and 2019, with a significant decrease among 
males in Yemen (annualised rate of change –0·94% 
[–1·72 to –0·14]) and a significant increase among females 
in Palau (1·00% [0·03 to 1·98]; table). However, for these 
data on males in Yemen, further investigation is needed 
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into the quality of the data due to conflict in this country 
during the study period.
Although temporal trends varied only slightly across 
these 12 countries, prevalence by age and sex differed 
much more. Globally in 2019, prevalence increased with 
age for females until age 80–84 years, after which it 
decreased, whereas for males prevalence increased up to 
age 35–39 years and then decreased in older age groups 
(appendix p 23). However, this global trend was not always 
reflected in the high-prevalence locations. In 2019, pre-
valence among males in the top 12 countries tended to 
decrease or flatten out in older age groups, with some 
countries observing peaks in prevalence in either young or 
middle-aged adults—eg, prevalence peaked at 52·73% 
(95% UI 42·13–63·31) in males aged 40–44 years in Nepal 
and at 42·29% (27·90–58·09) in males aged 25–29 years in 
Palau (figure 2). However, some countries had a more 
constant prevalence across age groups—eg, in Bangladesh, 
prevalence among males aged 20–24 years was 15·95% 
(10·88–22·62) and among males aged 80–84 years was 
27·23% (19·80–35·93; figure 2). Among females, preva-
lence often increased into older age groups. In Cambodia 
and Sri Lanka, prevalence of chewing tobacco use 
increased in each age group, with prevalences of 0·83% 
(0·31–1·86) in those aged 20–24 years and 35·71% 
(23·57–49·63) in those aged 70–74 years in Cambodia, and 
Females Males
Prevalence Annualised rate of change Prevalence Annualised rate of change







































































































































































































































































































































































































Data are given to two decimal places. Data in parentheses are 95% uncertainty intervals. Countries are ordered according to GBD super-region and region. GBD=Global 
Burden of Diseases, Injuries, and Risk Factors Study.
Table: Prevalence and annualised rate of change between 1990 and 2019 of current chewing tobacco use in the 12 locations with the highest age-
standardised prevalence of chewing tobacco use in either 1990 or 2019, by sex
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Figure 1: Age-standardised prevalence of chewing tobacco use in females (A) and males (B) aged 15 years and older, in 2019
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0·76% (0·29–1·66) in those aged 20–24 years, and 12·29% 
(4·89–24·71) in those aged 70–74 years in Sri Lanka 
(figure 2). Pakistan and Yemen had similar prevalences 
across age groups, whereas Madagascar and Palau had 
peaks in prevalence in females, among those aged 
45–49 years in Madagascar (12·79% [6·40–22·50]) and 
among those aged 25–29 years in Palau (41·12% 
[23·31–59·80]; figure 2).
Prevalence of chewing tobacco use was often quite high 
at young ages. In 2019, 126 (62%) of 204 locations had 
higher prevalence among males aged 15–19 years than the 
age-standardised prevalence for males older than 19 years; 
among females, 135 (66%) locations had a higher 
prevalence among those aged 15–19 years than the age-
standardised prevalence for females older than 19 years. 
For both sexes combined, seven locations—Marshall 
Islands, Federated States of Micronesia, Papua New 
Guinea, Bhutan, Guam, Northern Mariana Islands, and 
Palau—had prevalences of more than 10% in this age 
group (appendix pp 46–61). In 2019, south Asia and Oceania 
were the regions with the highest prevalence among people 
aged 15–19 years (figure 3; appendix p 29). Among males 
aged 15–19 years, the Marshall Islands had the highest 
prevalence of chewing tobacco use in 2019, at 32·50% 
(95% UI 22·82–42·74). Palau (30·55% [19·63–44·26]), 
Federated States of Micronesia (28·91% [19·52–39·75]), 
Northern Mariana Islands (27·78% [18·02–40·14]), and 
Bhutan (23·97% [16·34–33·82]) comprise the other top 
five countries for males in this age group (appendix 
pp 29, 43–58). The list is similar among females; the 
Federated States of Micronesia had the highest prevalence 
(22·55% [13·68–33·76]), with Northern Mariana Islands 
(21·62% [12·36–34·12]), Palau (20·85% [12·24–31·53]), 
Marshall Islands (17·04% [10·97–24·66]), and Papua New 
Guinea (13·24% [7·45–20·57]) comprising the rest of the 
top five countries among females in this age group 
(appendix pp 29, 43–58).
Unlike the prevalence of chewing tobacco use, the global 
age-standardised prevalence of smoking decreased signi-
ficantly between 1990 and 2019 (annualised rate of change: 
–1·21% [95% UI –1·26 to –1·16]). Among females in 2019, 
chewing tobacco use was more common than smoking 
tobacco use in eight of 12 countries, and in individuals 
aged 15–19 years in six of 12 countries. Similarly, among 
males in 2019, prevalence of chewing tobacco use was 
higher than smoking tobacco use in three of 12 countries 
and in individuals aged 15–19 years in four of 12 countries 
(appendix pp 24–27, 46–61).
Between 1990 and 2019, among the 12 countries with 
the highest prevalence of chewing tobacco use, nine had 
significant decreases in prevalence of smoking among 
males and seven had significant decreases among females 
Figure 2: Age-sex pattern of prevalence of chewing tobacco use in 2019 among the 12 locations with the highest age-standardised prevalence of chewing tobacco use in either 1990 or 2019, 
or both
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Figure 3: Age-standardised prevalence of chewing tobacco use versus prevalence of smoking among the 12 locations with the highest age-standardised 
prevalence of both-sex chewing tobacco use, in females (A) and males (B), in 1990–2019
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(appendix pp 38–45).  Among males in Nepal and India, 
the prevalence of chewing tobacco use surpassed the 
prevalence of smoking tobacco use in the past 5–10 years 
(figure 3). Among females, the difference in prevalence of 
chewing tobacco use versus prevalence of smoking 
tobacco use varied substantially by country (figure 3). 
For example, for females in Nepal and Myanmar, smok ing 
prevalence decreased significantly over 1990–2019, whereas 
the prevalence of chewing tobacco use was stable over 
this period. In Madagascar and Palau, the prevalence 
of chewing tobacco use among females surpassed the 
prevalence of smoking tobacco in the past decade 
(figure 3).
Two countries in 2019 had a higher prevalence of 
chewing tobacco use than of smoking tobacco use 
among people aged 15–19 years. Among males in 2019, 
Uzbekistan had a significantly higher prevalence of 
chewing tobacco use than of smoking tobacco use 
(12·68% [95% UI 6·92–21·30] vs 1·65% [1·03–2·49]; 
184 995 [100 912–310 674] chewing tobacco users vs 24 044 
[14 985–36 351] smokers; appendix pp 46–61). Among 
females, Bangladesh had significantly higher prevalence 
of chewing tobacco use than smoking tobacco use (5·08% 
[2·24–10·01] vs 1·06% [0·42–2·15]; 402 545 [177 719–793 059] 
chewing tobacco users vs 83 927 [33 649–162 605] smokers; 
appendix pp 46–61).
We did a sensitivity analysis to compare our final model 
to a model that only used chewing tobacco data (no 
adjusted unspecified smokeless tobacco data). Overall, the 
correlation of the two estimates was 0·821, and on average 
our final model was 0·83 percentage points lower globally 
than when just using the chewing tobacco data. Additional 
comparisons are provided in the appendix (pp 28–29).
Discussion
In 2019, 273·9 million (95% UI 258·5–290·9) people used 
chewing tobacco, and age-standardised prevalence for 
people aged 15 and older was 4·72% (4·46–5·01). 83·29% 
of chewing tobacco users live in south Asia, with 
185·8 million chewing tobacco users residing in India. 
Other countries with high prevalence of chewing tobacco 
use include Palau, Bangladesh, and Nepal, which together 
had 30·1 million chewing tobacco users in 2019. A major 
concern emerging from our analyses is that the prevalence 
of chewing tobacco use has remained constant and high. 
Of the 12 countries with the highest prevalences of chewing 
tobacco use, 11 had no significant decreases in prevalence 
of chewing tobacco use among males, whereas nine had 
significant decreases in prevalence of smoking tobacco use 
among males, and no countries had a significant decrease 
in prevalence of chewing tobacco use among females, 
whereas seven had significant decreases in prevalence of 
smoking tobacco use among females. Among females in 
2019, we found that use of chewing tobacco was more 
common than smoking in eight of the 12 highest prevalence 
countries for people aged 15 years and older, and among 
just those aged 15–19 years in six of 12 countries. Among 
males, prevalence of chewing tobacco use was higher than 
smoking in three of 12 countries and in individuals aged 
15–19 years in four of 12 countries. The serious adverse 
health effects resulting from chewing tobacco use11,12,15–17 
necessitate stronger regulations and policies than are 
currently in place, particularly in countries with persis-
tently high prevalence.
Much of the previous research on the prevalence of 
chewing tobacco use has focused on a particular country,18–20 
region,3,4,21 source,3,18–21 time period,11,20,21 or age group,5,22 
making formation of a comprehensive global picture of 
where chewing tobacco is used most, among which age 
groups and sexes, and how these trends have changed over 
time very difficult. Our study is a step towards under-
standing this full picture so that policy makers, public 
health officials, and advocacy organi sations have access to 
a full set of comparable estimates for use in addressing 
this harmful substance. Additionally, our aim to combine 
multiple sources and definitions of smokeless tobacco use 
across 204 locations has highlighted data synthesis issues 
due to definition variations and differences in data granu-
larity that should be addressed in future surveillance of 
smokeless tobacco use.
Underscoring the importance of strengthening control 
on use of chewing tobacco, we found that countries with 
high use of chewing tobacco had almost no change in 
prevalence between 1990 and 2019, whereas several of 
these locations had significant decreases in smoking 
prevalence during the same period. This finding is 
especially true among females, in whom the prevalence 
of chewing tobacco use was often close to, if not larger 
than, the prevalence of smoking. This trend in high-
prevalence countries has been noted previously,27 but our 
findings highlight this association over an extended time 
period and across the sexes. These findings might be due 
to a combination of factors, including less widespread 
application of the WHO FCTC articles on chewing 
tobacco,2,28 complex cultural reasons such as wider social 
acceptability and beliefs about associated benefits,6–8 and 
targeted advertising.29 Cambodia stands out as a place 
where the prevalence of chewing tobacco use is very high 
among females, particularly in comparison with among 
males, perhaps due to a variety of different environmental 
and cultural reasons.30 Because the prevalence of chewing 
tobacco use nears or surpasses the prevalence of smoking 
tobacco use in some countries, efforts must be intensified 
and the scope of tobacco control be expanded to explicitly 
address smokeless tobacco products.
Our findings also call attention to chewing tobacco use 
among adolescents, because seven countries had pre-
valences of more than 10% among people aged 15–19 years 
in 2019. Additionally, as observed among females, some 
locations with high chewing tobacco use among young 
people also had significantly higher prevalences of chewing 
tobacco use than of smoking tobacco use in 2019. These 
locations might be emerging markets for chewing tobacco, 
which should be reflected in how these countries enact the 
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FCTC articles. Initiation of use during youth, consumption, 
and patterns of use should also continue to be studied.
Our findings should be considered in the context of the 
limitations of the study. First, we did not quantify dual use 
of chewing tobacco and smoking, which is important to 
understand for both policy setting and burden implica-
tions.31 Tracking and understanding dual use might be 
important to uncover potential issues with targeted 
advertising, differential cessation success, or particularly 
problematic adolescent use.31,32 Second, our study relies on 
self-reported data and reporting biases might be present 
that vary across age groups, sexes, geographical regions, 
and socioeconomic statuses. The nature of these biases is 
not yet known, and previous studies indicate mixed scale 
and scope.33–35 However, because we measured prevalence 
and not amount of chewing tobacco used, under-reporting 
of smokeless tobacco use is unlikely to affect these results 
to a large degree. Third, although we aimed to better 
address the main limitation of modelling the preva-
lence of chewing tobacco use—a combination of data 
sparsity and compositional bias in survey questions 
across locations—higher quality data would improve our 
estimates and ensure that the location-year-age-sex ratios 
we used to adjust the unspecified smokeless tobacco data 
are accurate. Surveys that ask about locally relevant 
products would aid in providing estimates that are more 
precise and rely less on smoothing across age, time, and 
location. Improved questionnaires could also allow for 
analyses further differentiated by smokeless tobacco 
subtype or local products, or both, which would be 
beneficial for policy making. For example, a handful of 
Indian states banned gutkha (chewing tobacco preparation 
including betel nut) in 2013, which some studies have 
shown might have led people to purchase other types of 
smokeless tobacco,8,36 which cannot be captured in the 
current study. Additionally, both more granular data and 
additional data sources can help to avoid any instances 
where trends across age groups and over time are caused 
by different survey methods, although we do not believe 
that this limitation would substantially change our findings 
of this study. Future work should explore disaggre-
gation by other subgroups beyond age and sex. For 
example, previous studies have shown that socioeconomic 
status, educational attainment, and urbanicity might affect 
smokeless tobacco use.3 Additionally, subnational analysis 
will be important for future studies, because local evidence 
is crucial to local policy setting, and previous studies18,37 
have shown wide variation in the prevalence of chewing 
tobacco use within some countries. Specifically, an analysis 
of chewing tobacco use across subnational units in India 
should be prioritised.38,39
Chewing tobacco use continues to persist even with 
many countries’ commitment to the WHO FCTC articles, 
and there is a large opportunity for policies and pro-
grammes to better target the use of these products. In 
the absence of stronger policies that are effectively 
implemented, these trends might stay the same as they 
have in the past. Additionally, the popularity of these 
products among adolescents, especially in places where 
prevalence of smoking has not historically been high, 
indicates the potential for these products to gain users in 
locations that do not currently have high use of chewing 
tobacco. Even as countries face competing political priori-
ties and challenges from the tobacco industry, increased 
expansion, implementation, and enforcement of the 
WHO FCTC articles for smokeless tobacco in addition 
to locally targeted policies is integral to stemming the 
chewing tobacco epidemic.
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